Biomics Biotechnologies Co.

Nantong, China

Biomics Biotechnologies Co.

Nantong, China
SEARCH FILTERS
Time filter
Source Type

News Article | May 9, 2017
Site: marketersmedia.com

— The Psoriasis market report titled “Psoriasis - Pipeline Review, H1 2017" report provides an overview of Psoriasis clinical trials scenario. Browse the 209 Tables and 10 Figures, 150 Company Profiles, Spread across 648 Pages Report Available at http://www.reportsnreports.com/reports/983978-psoriasis-pipeline-review-h1-2017.html Psoriasis market companies are 3SBio Inc,AbbVie Inc,Abeome Corp,AbGenomics International Inc, Addex Therapeutics Ltd, Adello Biologics LLC, Advinus Therapeutics Ltd, Affibody AB, Albireo Pharma Inc, Alfacyte Ltd, Allergan Plc, Almirall SA, Alteogen Inc, Alvotech Iceland, Amgen Inc, Anacor Pharmaceuticals Inc, AnaptysBio Inc, ApoPharma Inc, Arbor Pharmaceuticals LLC, Arena Pharmaceuticals Inc, Argos Therapeutics Inc, Arrien Pharmaceuticals LLC, AstraZeneca Plc, Athenex Inc, Atlantic Bio Sci LLC, Aurigene Discovery Technologies Ltd, Aurinia Pharmaceuticals Inc, Bayer AG, Beta Pharma Inc, BioApex sro, Biocad, Biocon Ltd, BioLingus AG, BioMAS Ltd, Biomics Biotechnologies Co Ltd,Bionomics Ltd, Bionovis SA, BirchBioMed Inc,Boehringer Ingelheim GmbH,Brickell Biotech Inc,Bristol-Myers Squibb Company,C4X Discovery Holdings PLC,CalciMedica Inc,Can-Fite BioPharma Ltd,Celgene Corp,Cell Medica Ltd,Cellceutix Corp,ChemoCentryx Inc,Chipscreen Biosciences Ltd,ChironWells GmbH,Coherus BioSciences Inc,Compugen Ltd,Concenter BioPharma Silkim Ltd,Crescita Therapeutics Inc,CritiTech Inc,Curapel Ltd,Dermala Inc,Dr. August Wolff GmbH & Co KG Arzneimittle,DURECT Corp,EA Pharma Co Ltd,Eli Lilly and Company,ELORAC Inc,Exicure Inc,Foamix Pharmaceuticals Ltd,Forward Pharma A/S,Galapagos NV,Galderma SA many more.. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=983978 . The Psoriasis market pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology). The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 21, 44, 42, 1, 103, 32 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively. Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Reasons to buy • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/983978-psoriasis-pipeline-review-h1-2017.html


This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.


Patent
BIOMICS BIOTECHNOLOGIES Co. | Date: 2010-03-30

The present invention relates to a modified oligonucleotide, its preparation and application. The invention enables stabilizing the oligonucleotide by introducing a relatively small amount of modified nucleotide at specific UA/UA and/or CA/UG and/or UG/CA site of the oligonucleotide, therefore to decrease the modification-related cytotoxicity and compromising effects on the biological activity.


Patent
Biomics Biotechnologies Co. and Benitec Ltd | Date: 2011-10-27

RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.


Patent
Biomics Biotechnologies Co. | Date: 2013-03-06

The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.


The present invention provides a PCR based high-throughput method for preparing full-sites siRNA polynucleotide pool, comprising: DNase I random digestion; Loop-1 phosphate linker ligation; single PCR amplification; a type III restriction/modification enzyme digestion; blunt ending; Loop-2 phosphate linker ligation; double primer PCR; FokI digestion and cloning into an siRNA expression vector. The present invention enables the use of a type III restriction/modification enzyme linkers mediated PCR method for high-throughput preparing an siRINA polynucleotide pool, in which the functional length of siRNAs can be controllably distributed from 19-23 bp, thus completely mimic the natural siRNA length diversity, specially suitable for RNAi therapeutic targets screening. The present invention overcomes the bottlenecks and drawbacks of conventional siRNA polynucleotide pool construction technologies.


Patent
Biomics Biotechnologies Co. | Date: 2015-07-22

This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.


Patent
Biomics Biotechnologies Co. | Date: 2015-08-14

Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.


Patent
Biomics Biotechnologies Co. | Date: 2012-02-08

The present invention relates to a modified oligonucleotide, its preparation and application. The invention eables stabilizing the oligonucleotide by introducing a relatively small amount of modified nucleotide at specific UA/UA and/or CA/UG and/or UG/CA site of the oligonucleotide, therefore to decrease the modification-related cytotoxicity and compromising effects on the biological activity.


Patent
Biomics Biotechnologies Co. | Date: 2012-03-08

This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.

Loading Biomics Biotechnologies Co. collaborators
Loading Biomics Biotechnologies Co. collaborators